X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (466) 466
index medicus (301) 301
male (299) 299
female (254) 254
animals (215) 215
1-alkyl-2-acetylglycerophosphocholine esterase (183) 183
middle aged (183) 183
1-alkyl-2-acetylglycerophosphocholine esterase - blood (179) 179
1-alkyl-2-acetylglycerophosphocholine esterase - metabolism (162) 162
atherosclerosis (151) 151
aged (133) 133
risk factors (125) 125
adult (118) 118
inflammation (108) 108
1-alkyl-2-acetylglycerophosphocholine esterase - genetics (95) 95
biochemistry & molecular biology (88) 88
biomarkers - blood (80) 80
mice (76) 76
lipids (75) 75
phospholipase a (75) 75
phospholipases a - metabolism (71) 71
c-reactive protein (70) 70
1-alkyl-2-acetylglycerophosphocholine esterase - antagonists & inhibitors (69) 69
platelet-activating-factor (69) 69
platelet activating factor - metabolism (67) 67
low-density-lipoprotein (62) 62
coronary-heart-disease (61) 61
phospholipases (61) 61
rats (60) 60
enzymes (56) 56
cholesterol (55) 55
cardiac & cardiovascular systems (54) 54
cardiovascular disease (51) 51
lipoproteins (51) 51
research (50) 50
cardiovascular (47) 47
peripheral vascular disease (47) 47
plasma (47) 47
platelet-activating factor (47) 47
cells, cultured (45) 45
phospholipases a2 (45) 45
pharmacology & pharmacy (44) 44
treatment outcome (43) 43
case-control studies (42) 42
phospholipases a - blood (42) 42
article (41) 41
dose-response relationship, drug (41) 41
lipoprotein-associated phospholipase a2 (41) 41
platelet activating factor (41) 41
coronary-artery-disease (38) 38
lipoproteins, ldl - blood (38) 38
time factors (37) 37
abridged index medicus (36) 36
analysis (36) 36
biomarkers (36) 36
cardiovascular-disease (36) 36
coronary heart disease (36) 36
enzyme inhibitors - pharmacology (36) 36
expression (36) 36
oxidative stress (36) 36
risk (35) 35
myocardial-infarction (33) 33
paf-acetylhydrolase (33) 33
gene expression (32) 32
microtubule-associated proteins - genetics (32) 32
cell biology (31) 31
cholesterol, ldl - blood (31) 31
endocrinology & metabolism (31) 31
lipoprotein-associated phospholipase a (31) 31
low density lipoproteins (31) 31
lp-pla2 (31) 31
activating-factor-acetylhydrolase (30) 30
double-blind method (30) 30
activating-factor acetylhydrolase (29) 29
aged, 80 and over (29) 29
atherosclerosis - drug therapy (29) 29
microtubule-associated proteins - metabolism (29) 29
platelet-activating factor acetylhydrolase (29) 29
proteins (29) 29
1-alkyl-2-acetylglycerophosphocholine esterase - drug effects (28) 28
disease models, animal (28) 28
heart-disease (28) 28
phospholipase a2 (28) 28
phospholipases a - antagonists & inhibitors (28) 28
platelet activating factor - pharmacology (28) 28
research article (28) 28
disease (27) 27
human-plasma (27) 27
oxidation-reduction (27) 27
studies (27) 27
c-reactive protein - metabolism (26) 26
cardiology (26) 26
lipoproteins, hdl - blood (26) 26
lipoproteins, ldl - metabolism (26) 26
medicine (26) 26
medicine & public health (26) 26
middle-aged men (26) 26
neurosciences (26) 26
physiological aspects (26) 26
rabbits (26) 26
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2008, Volume 51, Issue 17, pp. 1653 - 1662
The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans Bonnie Ky, Anne Burke, Sotirios Tsimikas, Megan L.... 
Cardiovascular | Internal Medicine | C-REACTIVE PROTEIN | COA REDUCTASE INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | OXIDANT STRESS | APOLIPOPROTEIN B-100 | STATIN THERAPY | LOW-DENSITY-LIPOPROTEIN | PHOSPHOLIPASE A | CORONARY-HEART-DISEASE | CIRCULATING OXIDIZED LDL | LIPID-LOWERING THERAPY | 1-Alkyl-2-acetylglycerophosphocholine Esterase - blood | Autoantibodies - blood | Humans | Middle Aged | Male | Apolipoproteins B - blood | Apolipoproteins B - drug effects | 1-Alkyl-2-acetylglycerophosphocholine Esterase - drug effects | Time Factors | Pyrroles - administration & dosage | Aged, 80 and over | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Phospholipids - blood | Surveys and Questionnaires | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Double-Blind Method | Drug Administration Schedule | Cholesterol, LDL - drug effects | Treatment Outcome | Biomarkers - blood | Atorvastatin Calcium | Pyrroles - pharmacology | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Oxidative Stress - drug effects | Anticholesteremic Agents - pharmacology | Oxidative stress | Enzymes | Low density lipoproteins | Lipids | Pravastatin | Coronary heart disease | Lipoprotein A | Cholesterol | Cardiovascular agents | Antilipemic agents | Hypercholesterolemia | Phospholipases | Enzyme-linked immunosorbent assay | Viral antibodies | Antibodies | Plasma | Immunoassay | Cardiovascular disease | Triglycerides | Apolipoproteins | Low density lipoprotein | Studies | Biomarkers | Statins
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 2013, Volume 2, Issue 5, pp. e000360 - 13
Journal Article
Journal Article
Atherosclerosis, ISSN 0021-9150, 2003, Volume 170, Issue 1, pp. 21 - 29
Obesity is an important risk factor of atherosclerosis; however, the mechanism of proatherogenic effect of obesity is not definitely established. Recent... 
Oxidative stress | Obesity | Leptin | Atherosclerosis | Paraoxonase | Platelet-activating factor acetylhydrolase | Antioxidant potential | platelet-activating factor acetylhydrolase | antioxidant potential | atherosclerosis | HUMAN SERUM PARAOXONASE | C-REACTIVE PROTEIN | LOW-DENSITY-LIPOPROTEIN | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | leptin | ACUTE-PHASE RESPONSE | FACTOR-ACETYLHYDROLASE | ENDOTHELIAL-CELLS | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | PLATELET-ACTIVATING-FACTOR | paraoxonase | oxidative stress | obesity | APOLIPOPROTEIN-A-I | Aryldialkylphosphatase - blood | Biomarkers - urine | Rats, Wistar | 1-Alkyl-2-acetylglycerophosphocholine Esterase - blood | Antioxidants - metabolism | Male | Statistics as Topic | Hyperlipidemias - enzymology | Paraoxon - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Dose-Response Relationship, Drug | 1-Alkyl-2-acetylglycerophosphocholine Esterase - drug effects | Leptin - blood | Lactones - administration & dosage | Aryldialkylphosphatase - drug effects | Leptin - pharmacology | Disease Models, Animal | Phenylacetates - administration & dosage | Models, Cardiovascular | Rats | Biomarkers - blood | Isoprostanes - urine | Animals | Cholinesterase Inhibitors - administration & dosage | Hyperlipidemias - etiology | Oxidative Stress - drug effects | Isoprostanes - blood | Chronic Disease
Journal Article
Journal Article
Journal Article
European journal of preventive cardiology, 03/2017, Volume 24, Issue 5, p. 492
Journal Article
Journal Article
Expert review of cardiovascular therapy, 01/2015, Volume 13, Issue 1, p. 33
Elevated levels of phospholipase A2 have been linked to atherosclerotic plaque progression, instability via promoting inflammation and subsequent acute... 
1-Alkyl-2-acetylglycerophosphocholine Esterase - drug effects | Animals | Atherosclerosis - drug therapy | Inflammation - drug therapy | Humans | Oximes - therapeutic use | Risk | Benzaldehydes - therapeutic use | Plaque, Atherosclerotic - drug therapy
Journal Article
Canadian Journal of Cardiology, ISSN 0828-282X, 2010, Volume 26, pp. 27A - 31A
Lipoprotein-associated phospholipase A2 is an enzyme produced by inflammatory cells, which binds to apolipoprotein B-containing lipoprotein